The Write Stuff: Best Practices in Scientific Writing for Peer Review

Main Article Content

Ellen McCarthy Julia Saiz Shimosato

Abstract

Session Description: Today’s healthcare industry is unapologetically data-driven. From virtual biotech start-ups to big pharma and independent research agencies, making data available to the public, whether positive or negative, is an integral component of any research and development effort. Among all the means available for scientific communications, peer-reviewed publications remain the gold standard platform for the public release and vetting of biomedical data, from preclinical to advanced-stage clinical studies. And behind most effective peer-review communication strategies and efforts, there is craft, knowledge and a mix of experience, intuition and resourcefulness.


Our session will focus on the rules and norms shaping the peer-review publication ecosystem, discussing best practices and industry guidance, providing you with a comprehensive understanding of the approach, the standards, the development, and ultimately the publication, of biomedical manuscripts. Topics to be covered include: conceptualization: how different types of studies make it into manuscripts; steps to publication; industry guidance and authorship criteria: GPP3 and ICMJE; defining manuscripts: whitepaper vs peer-review publication vs editorial; journal selection; and management of the peer-review process.


As publications professionals in the pharmaceutical industry, we have provided strategic and executional support to clients around the world. Our goal is always the same: to excel as publication partners, from concept to print. We look forward to seeing you on October 24, 2018, for an informative and insightful session on best practices in peer-review publications.

Downloads

Download data is not yet available.

Article Details

How to Cite
McCarthy, E., & Shimosato, J. (2018). The Write Stuff: Best Practices in Scientific Writing for Peer Review. Blockchain in Healthcare Today. Retrieved from https://blockchainhealthcaretoday.com/index.php/journal/article/view/74
Section
Track: Knowledge and Leadership
Author Biographies

Ellen McCarthy, Cadent Medical Communications, Managing Director

https://syneoshealth.com/

Ellen brings a unique blend of scientific expertise and strategic thinking to her role as Managing Director at Cadent Medical Communications. Throughout her career in medical education and healthcare advertising, she has amassed significant experience developing strategic communication platforms for numerous educational and promotional initiatives, including peer-to-peer, medical affairs and publications.  She relishes in learning new science and working with her team and clients to bring it to life for the HCP audience.
 
Ellen’s scientific repertoire spans numerous therapeutic categories across accounts both domestic and global. She has worked extensively in the fields of oncology (immunotherapy, prostate cancer, hepatocellular carcinoma, renal cell carcinoma, CML, oncology diagnostics, and oncology supportive care), dermatology (psoriasis), gastroenterology (IBD [ulcerative colitis and Crohn’s disease]) rheumatology/immunology (lupus, osteoarthritis, and rheumatoid arthritis), respiratory (COPD), neurology (TTR-FAP and movement disorders), as well as cardiology (anticoagulation) and diabetes (SGLT2 inhibition), supporting products and brands from development to launch and lifecycle management.

Prior to joining Cadent in 2017, Ellen was SVP, Director Medical and Scientific Services at The Bloc and prior to that worked at Ogilvy Healthworld. She received her doctorate degree in cancer biology from Columbia University where she was the recipient of the Rover Award for Outstanding Graduate Student Achievement. Ellen’s work has been published in several peer-reviewed journals.

Julia Saiz Shimosato, Syneos Health, SVP

https://syneoshealth.com/

Julia has over 15 years of experience in the field of medical communications, education, and advertising.  She holds a doctoral degree in molecular genetics from the University of Salamanca (Spain) and spent 5 years as a postdoctoral research fellow, later associate, at Memorial Sloan Kettering Cancer Center, New York, NY, investigating the mechanisms of cell division control and their relationship to potential oncogenic processes.

Working with pharmaceutical, biotech clients, academic institutions, and professional societies, Julia has provided strategic solutions via publications, educational programs, and promotional campaigns, from the development of concepts and messaging, to final deliverables. Her expertise includes genetic diseases, rheumatology/immunology, cardiovascular and respiratory medicine, and oncology.

Julia has an extensive track record in publications, from conceptual multi-year planning, to successful execution of high-quality, high-science manuscripts or congress presentations (phase I-III clinical trials, as well as clinical biomarker discovery data sets). Among other brands, Julia led the multi-indication publication efforts for Erbitux (cetuximab) and Tarceva (erlotinib) when these products transitioned from widely-defined indications to biomarker-based clinical use. Julia has also worked developing promotional and medical strategies for major brands, such as Erbitux (cetuximab), Velcade (bortezomib), Empliciti (elotuzumab), Orkambi (lumacaftor/ivacaftor), Eliquis (apixaban) and Cimzia (certolizumab pegol), playing an instrumental role in developing positioning platforms and strategic messaging from inception to market research. 

Recently, Julia has been supporting several major brands in the field of oncology/hematology, and immunology including multiple antibodies and large molecules, both for US and global teams. Julia acts as medical director, leading content development and management for publications and other scientific output.